Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Urine Test Predicts COPD Flares Before Symptoms Appear

By LabMedica International staff writers
Posted on 22 Nov 2024

Chronic obstructive pulmonary disease (COPD) affects over 400 million people worldwide and is expected to become the third leading cause of death by 2030. More...

COPD is characterized by persistent symptoms, including breathlessness, cough, and wheezing, along with ongoing impairment in lung function. At times, the symptoms worsen, leading to exacerbations. These exacerbations are triggered by various factors, such as viral and bacterial infections, as well as a series of smaller disruptions that lead to the destabilization of the disease. COPD exacerbations can be detrimental as they cause further damage to the lungs, making prevention essential for improving quality of life and reducing the risk of death. Current methods of measuring inflammation in COPD typically involve blood or sputum samples taken during exacerbations, compared to stable visits occurring weeks apart. However, these approaches have not led to a widely adopted test due to limitations in sensitivity and specificity, as well as difficulties in obtaining timely samples for proper management. The challenge now is to develop near-patient tests capable of detecting and analyzing the heterogeneous inflammatory response that precedes an exacerbation. Now, researchers have applied artificial intelligence (AI) to urine samples to predict when COPD symptoms will flare up.

Global Access Diagnostics (Bedford, UK) has developed a prototype test called Headstart, a remote patient monitoring platform that measures five biomarkers in urine. Headstart is currently being tested to detect the early signs of exacerbation with enough reliability to help patients determine whether they need to seek medical attention. A study led by the University of Leicester (Leicester, UK) involved patients using this simple daily dipstick test to monitor their urine and sending the results to researchers via their mobile phones. Using AI to analyze the data, the researchers were able to predict a deterioration in symptoms up to one week in advance, providing an opportunity to adjust treatment to prevent or reduce flare-ups.

The study began by analyzing urine samples from 55 COPD patients to identify any changes in urine composition that could precede a worsening of symptoms. This led to the identification of a set of biomarkers—molecules that shift when COPD is deteriorating. The researchers then asked 105 additional COPD patients to use the Headstart device daily over six months, sending their results back to the researchers via mobile phones. AI, specifically an artificial neural network, was employed to examine fluctuations in these biomarkers and predict when a flare-up would occur. The study, published in ERJ Open Research, demonstrated that the AI analysis could predict an exacerbation approximately seven days before any symptoms appeared.

"Our study first explored many substances in urine samples from people with COPD during a flare up and when they were stable,” said Professor Chris Brightling from the University of Leicester. “We found that a small number of these substances could identify a flare up. We then followed up a group of people with COPD and tested five substances daily. This allowed us to develop the risk prediction or forecasting AI-tool. We found the AI tool could reliably predict a flare up in symptoms seven days prior to a diagnosis.”


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.